Results 201 to 210 of about 308,418 (340)

Paclitaxel-induced cognitive impairment: mechanistic insights. [PDF]

Front Pharmacol
Alhowail AH.
europepmc   +1 more source

Paclitaxel vs cyclophosphamide in peripheral blood stem cell mobilization

, 1999
Udit Verma, Bernt van den Blink, Ravindran Pillai, Jasvinder Chawla, Amitabha Mazumder, Herbert B. Herscowitz, Kenneth R. Meehan   +6 more
openalex   +1 more source

A Phase I study of raltitrexed and paclitaxel given every 3 weeks to patients with solid tumors [PDF]

, 1999
Everett E. Vokes, Boon Cher Goh, Donna Bertucci, Nicholas J. Vogelzang, Sridhar Mani, Mark J. Ratain   +5 more
openalex   +1 more source

Everolimus‐Coated Laser‐Cut Self‐Expandable Metallic Stent Suppresses Stent‐Induced Tissue Hyperplasia in a Rat Gastric Outlet

Advanced NanoBiomed Research, EarlyView.
Everolimus‐coated laser‐cut self‐expandable metallic stents suppress stent‐induced tissue hyperplasia in the gastric outlet by reducing inflammation, fibrosis, and smooth muscle proliferation. Herein, we demonstrate the mechanical stability, sustained drug release, and histological benefits in a rat gastric outlet model, suggesting potential for ...
Yubeen Park, Chae Eun Yun, Dong‐Sung Won, Song Hee Kim, Ji Won Kim, Seung Jin Eo, Seokin Kang, Hyun‐Do Jung, Do Hoon Kim, Jun‐Kyu Park, Jung‐Hoon Park   +10 more
wiley   +1 more source

Pitavastatin is a novel Mcl-1 inhibitor that overcomes paclitaxel resistance in triple-negative breast cancer. [PDF]

Exp Hematol Oncol
Ko D, Park S, Park M, Kim S, Park JM, Seo J, Nam KD, Kang YK, Farrand L, Jung E, Kim YJ, Kim JY, Seo JH.   +12 more
europepmc   +1 more source

A phase I–II study of bi-weekly paclitaxel as first-line treatment in metastatic breast cancer

, 1998
Karen A. Gelmon, Anthony W. Tolcher, Séamus O’Reilly, Craig I. Campbell, C. Bryce, Tamara Shenkier, Joseph Ragaz, D. Ayers, Lynne Nakashima, S. Rielly, Hélène Dulude   +10 more
openalex   +1 more source

Metabolism‐Regulating Nanomedicines for Cancer Therapy

Advanced NanoBiomed Research, EarlyView.
This review highlights metabolism‐regulating nanomedicines designed to target glycolytic, lipid, amino acid, and nucleotide pathways in tumors. By incorporating metabolism‐regulating agents into versatile nanocarriers such as liposomes, micelles, dendrimers, and engineered bacteria, these platforms achieve targeted delivery, controlled release ...
Xiao Wu, Shiyi Geng, Jian Yang
wiley   +1 more source

Nanomicellar Prodrug Delivery of Glucose-Paclitaxel: A Strategy to Mitigate Paclitaxel Toxicity

International Journal of Nanomedicine
Didi Yan,1 Xinyue Ma,1 Yixin Hu,1 Guogang Zhang,1 Beibei Hu,1 Bo Xiang,2 Xiaokun Cheng,1,3 Yongshuai Jing,1 Xi Chen1,4 1College of Chemical and Pharmaceutical Engineering, Hebei University of Science and Technology, Shijiazhuang, 050018, People’s ...
Yan D, Ma X, Hu Y, Zhang G, Hu B, Xiang B, Cheng X, Jing Y, Chen X   +8 more
doaj  

Paclitaxel-based therapy in non-small-cell lung cancer: Improved third generation chemotherapy

, 1999
F. Anthony Greco, John D. Hainsworth
openalex   +1 more source

Nanobiotechnology‐Based Approaches for Targeted Glioma Therapy

Advanced NanoBiomed Research, EarlyView.
Nanoparticle systems cross the blood–brain barrier to deliver drugs precisely to glioma cells. Lipid, polymeric, and magnetic carriers enable controlled release, tumor targeting, and microenvironment modulation. These nanoplatforms enhance chemotherapy, radiotherapy, and immunotherapy, improving therapeutic efficacy while reducing systemic toxicity ...
Jinwei Li, Yibo He, Yang Zhang, Lining Arnold Ju, Yao Wang, Jianxuan Zhou, Yinying Chai, Xuhui Hui, ShiYuan Tong, Si Zhang, Yanli Tan, Yinyan Wang   +11 more
wiley   +1 more source